The Effect of Intravenous Lidocaine on Trigeminal Neuralgia: A Randomized Double Blind Placebo Controlled Trial

Evmorfia Stavropoulou, Erifili Argyra, Panagiotis Zis, Athina Vadalouca, Ioanna Siafaka, Evmorfia Stavropoulou, Erifili Argyra, Panagiotis Zis, Athina Vadalouca, Ioanna Siafaka

Abstract

Trigeminal neuralgia is the most common neuralgia. Its therapeutic approach is challenging as the first line treatment often does not help, or even causes intolerable side effects. The aim of our randomized double blind, placebo controlled, crossover study was to investigate in a prospective way the effect of lidocaine in patients with trigeminal neuralgia. Twenty patients met our inclusion criteria and completed the study. Each patient underwent four weekly sessions, two of which were with lidocaine (5 mgs/kg) and two with placebo infusions administered over 60 minutes. Intravenous lidocaine was superior regarding the reduction of the intensity of pain, the allodynia, and the hyperalgesia compared to placebo. Moreover, contrary to placebo, lidocaine managed to maintain its therapeutic results for the first 24 hours after intravenous infusion. Although, intravenous lidocaine is not a first line treatment, when first line medications fail to help, pain specialists may try it as an add-on treatment. This trial is registered with NCT01955967.

Figures

Figure 1
Figure 1
Intensity of pain according to VAS score (vertical axis), during the first 24 hours after treatment (horizontal axis) between lidocaine (5 mg per kilogram of patient's weight) and placebo treatment groups.

References

    1. Merksey H., Bogduk N. Descriptions of Chronic Pain Syndromes and Definitions of Pain Term. Seattle, Wash, USA: IASP Press; 1994. Classification of chronic pain; pp. 59–71.
    1. Cruccu G., Gronseth G., Alksne J., et al. AAN-EFNS guidelines on trigeminal neuralgia management. European Journal of Neurology. 2008;15(10):1013–1028. doi: 10.1111/j.1468-1331.2008.02185.x.
    1. Gilbert C. R., Hanson I. R., Brown A. B., Higinson R. A. Intravenous use of xylocaine. Current Researches in Anesthesia & Analgesia. 1951;30(6):301–313.
    1. de Clive-Lowe S. G., Desmond J., North J. Intravenous lignocaine anaesthesia. Anaesthesia. 1958;13(2):138–146.
    1. Barlett E. E., Hutaserani O. Xylocaine for the postoperative pain. Anesthesia and Analgesia. 1961;40:296–304.
    1. Khaliq W., Alam S., Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews. 2007;(2)CD004846
    1. Arai Y. C., Hatakeyama N., Nishihara M., Ikeuchi M., Kurisuno M., Ikemoto T. Intravenous lidocaine and magnesium for management of intractable trigeminal neuralgia: a case series of nine patients. Journal of Anesthesia. 2013;27(6):960–962. doi: 10.1007/s00540-013-1641-5.
    1. Nagaro T., Shimizu C., Inoue H., et al. The efficacy of intravenous lidocaine on various types of neuropathic pain. Japanese Journal of Anesthesiology. 1995;44(6):862–867.
    1. Mao J., Chen L. L. Systemic lidocaine for neuropathic pain relief. Pain. 2000;87(1):7–17. doi: 10.1016/S0304-3959(00)00229-3.
    1. Tanelian D. L., Brose W. G. Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine. Anesthesiology. 1991;74(5):949–951.
    1. Lauretti G. R. Mechanisms of analgesia of intravenous lidocaine. Revista Brasileira de Anestesiologia. 2008;58(3):280–286. doi: 10.1590/S0034-70942008000300011.
    1. Vadalouca A., Raptis E., Moka E., Zis P., Sykioti P., Siafaka I. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Practice. 2012;12(3):219–251. doi: 10.1111/j.1533-2500.2011.00485.x.
    1. Chaplan S. R., Bach F. W., Shafer S. L., Yaksh T. L. Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. Anesthesiology. 1995;83(4):775–785. doi: 10.1097/00000542-199510000-00017.
    1. Thomson P. D., Melmon K. L., Richardson J. A., et al. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Annals of Internal Medicine. 1973;78(4):499–508.
    1. Tremont-Lukats I. W., Hutson P. R., Backonja M. M. A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. Clinical Journal of Pain. 2006;22(3):266–271. doi: 10.1097/01.ajp.0000169673.57062.40.
    1. Attal N., Rouaud J., Brasseur L., Chauvin M., Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology. 2004;62(2):218–225.
    1. Khawaja N., Yilmaz Z., Renton T. Case studies illustrating the management of trigeminal neuropathic pain using topical 5% lidocaine plasters. The British Journal of Pain. 2013;7(2):107–113. doi: 10.1177/2049463713483459.
    1. Jones B., Kenward M. G. Design and Analysis of Cross over Trials. Vol. 98. New York, NY, USA: CRC Press; 2003.
    1. Attal N., Gaudé V., Brasseur L., et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology. 2000;54(3):564–574.
    1. Bach F. W., Jensen T. S., Kastrup J., Stigsby B., Dejgård A. The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain. 1990;40(1):29–34. doi: 10.1016/0304-3959(90)91047-M.
    1. Ferrante F. M., Paggioli J., Cherukuri S., Arthur G. R. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Anesthesia and Analgesia. 1996;82(1):91–97. doi: 10.1097/00000539-199601000-00016.
    1. Tremont-Lukats I. W., Challapalli V., McNicol E. D., Lau J., Carr D. B. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesthesia and Analgesia. 2005;101(6):1738–1749. doi: 10.1213/01.ANE.0000186348.86792.38.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren